Yusuke Amanuma

Yusuke Amanuma

Auto-generated profile, based on publicly available information

Yusuke Amanuma

Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAyaka Mizumoto
Ayaka Mizumoto
SOShinya Ohashi
Shinya Ohashi
KHKenshiro Hirohashi
Kenshiro Hirohashi
YAYusuke Amanuma
Yusuke Amanuma
TMTomonari Matsuda
Tomonari Matsuda
MMManabu Muto
Manabu Muto
Acetaldehyde is a highly reactive compound that causes various forms of damage to DNA, including DNA adducts, single- and/or double-strand breaks (DSBs), point mutations, sister chromatid exchanges (SCEs), and DNA–DNA cross-links. Among these, DNA adducts such as N2-ethylidene-2′-deoxyguanosine, N2-ethyl-2′-deoxyguanosine, N2-propano-2′-deoxyguanosine, and N2-etheno-2′-deoxyguanosine are central to acetaldehyde-mediated DNA damage because they are associated with the induction of DNA mutations, DNA–DNA cross-links, DSBs, and SCEs. Acetaldehyde is produced endogenously by alcohol metabolism and is catalyzed by aldehyde dehydrogenase 2 (ALDH2). Alcohol consumption increases blood and salivary acetaldehyde levels, especially in individuals with ALDH2 polymorphisms, which are highly associated with the risk of squamous cell carcinomas in the upper aerodigestive tract. Based on extensive epidemiological evidence, the International Agency for Research on Cancer defined acetaldehyde associated with the consumption of alcoholic beverages as a “group 1 carcinogen” (definite carcinogen) for the esophagus and/or head and neck. In this article, we review recent advances from studies of acetaldehyde-mediated carcinogenesis in the squamous epithelium, focusing especially on acetaldehyde-mediated DNA adducts. We also give attention to research on acetaldehyde-mediated DNA repair pathways such as the Fanconi anemia pathway and refer to our studies on the prevention of acetaldehyde-mediated DNA damage.

1 August 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MYMasahiro Yoshioka
Masahiro Yoshioka
SOShinya Ohashi
Shinya Ohashi
TITomomi Ida
Tomomi Ida
YNYukie Nakai
Yukie Nakai
OKOsamu Kikuchi
Osamu Kikuchi
MMManabu Muto
Manabu Muto
Epidermal growth factor receptor (EGFR) plays a pivotal role in the pathophysiology of esophageal squamous cell carcinoma (ESCC). However, the clinical effects of EGFR inhibitors on ESCC are controversial. This study sought to identify the factors determining the therapeutic efficacy of EGFR inhibitors in ESCC cells. Immortalized-human esophageal epithelial cells (EPC2-hTERT), transformed-human esophageal epithelial cells (T-Epi and T-Mes), and ESCC cells (TE-1, TE-5, TE-8, TE-11, TE-11R, and HCE4) were treated with the EGFR inhibitors erlotinib or cetuximab. Inhibitory effects on cell growth were assessed by cell counting or cell-cycle analysis. The expression levels of genes and proteins such as involucrin and cytokeratin13 (a squamous differentiation marker), E-cadherin, and vimentin were evaluated by real-time polymerase chain reaction or western blotting. To examine whether mesenchymal phenotype influenced the effects of EGFR inhibitors, we treated T-Epi cells with TGF-β1 to establish a mesenchymal phenotype (mesenchymal T-Epi cells). We then compared the effects of EGFR inhibitors on parental T-Epi cells and mesenchymal T-Epi cells. TE-8 (mesenchymal-like ESCC cells)- or TE-11R (epithelial-like ESCC cells)-derived xenograft tumors in mice were treated with cetuximab, and the antitumor effects of EGFR inhibitors were evaluated. Cells were classified as epithelial-like or mesenchymal-like phenotypes, determined by the expression levels of E-cadherin and vimentin. Both erlotinib and cetuximab reduced cell growth and the ratio of cells in cell-cycle S phase in epithelial-like but not mesenchymal-like cells. Additionally, EGFR inhibitors induced squamous cell differentiation (defined as increased expression of involucrin and cytokeratin13) in epithelial-like but not mesenchymal-like cells. We found that EGFR inhibitors did not suppress the phosphorylation of EGFR in mesenchymal-like cells, while EGFR dephosphorylation was observed after treatment with EGFR inhibitors in epithelial-like cells. Furthermore, mesenchymal T-Epi cells showed resistance to EGFR inhibitors by circumventing the dephosphorylation of EGFR signaling. Cetuximab consistently showed antitumor effects, and increased involucrin expression in TE-11R (epithelial-like)-derived xenograft tumors but not TE-8 (mesenchymal-like)-derived xenograft tumors. The factor determining the therapeutic effects of EGFR inhibitors in ESCC cells is the phenotype representing the epithelial-like or mesenchymal-like cells. Mesenchymal-like ESCC cells are resistant to EGFR inhibitors because EGFR signaling is not blocked. EGFR inhibitors show antitumor effects on epithelial-like ESCC cells accompanied by promotion of squamous cell differentiation.

16 January 2026 in Esophagus
Verified
Journal Article
Open access
PDF file
MTMasashi Tamaoki
Masashi Tamaoki
AYAkira Yokoyama
Akira Yokoyama
CKChikatoshi Katada
Chikatoshi Katada
KHKenshiro Hirohashi
Kenshiro Hirohashi
YMYosuke Mitani
Yosuke Mitani
MMManabu Muto
Manabu Muto
Background: Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control. Methods: This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model. Results: The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3–76.6). During the median follow-up of 17.8 months (range, 1.7–69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% ( P = 0.008), 64.6% vs. 0% ( P < 0.001), and 97.0% vs. 85.7% ( P = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051–30.124, P = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% ( P = 0.015) and 85.7% vs. 94.6% ( P = 0.015), respectively. Conclusions: Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.

1 May 2013 in Gastroenterology
Verified
Journal Article
Closed access
YAYusuke Amanuma
Yusuke Amanuma
SOShinya Ohashi
Shinya Ohashi
MTMihoko Tsurumaki
Mihoko Tsurumaki
OKOsamu Kikuchi
Osamu Kikuchi
DKDaisuke Kuriyama
Daisuke Kuriyama
MMManabu Muto
Manabu Muto

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KHKenshiro Hirohashi
Kenshiro Hirohashi
SOShinya Ohashi
Shinya Ohashi
YAYusuke Amanuma
Yusuke Amanuma
YNYukie Nakai
Yukie Nakai
SMShin'Ichi Miyamoto
Shin'Ichi Miyamoto
MMManabu Muto
Manabu Muto

1 May 2013 in Gastroenterology
Verified
Journal Article
Closed access
SOShinya Ohashi
Shinya Ohashi
MTMihoko Tsurumaki
Mihoko Tsurumaki
OKOsamu Kikuchi
Osamu Kikuchi
DKDaisuke Kuriyama
Daisuke Kuriyama
YAYusuke Amanuma
Yusuke Amanuma
MMManabu Muto
Manabu Muto